Afon Technology, a medtech company in Wales, aims to transform diabetes management with its non-invasive glucose monitoring device, GlucowearTM. The company recently partnered with Sony UK Technology Centre for manufacturing, a key step towards bringing the device to market.
Satpal Biant, Head of Public Sector, UK & Ireland SAP, explores why the NHS must keep up with digital demand while reducing costs and improve service continuity for a truly integrated healthcare asset to be formed.
This World Mental Health Day, we spoke to seven business leaders on the importance of mental health awareness and what all employers can do to support their staff.
Here, Mark Creighton, CEO of Avado, speaks on the urgent need to overhaul our skills system and focus on the youth of tomorrow, ensuring they have the capabilities needed to thrive as we enter a new phase of hybrid working.
Holly Smith, Senior Solutions Consultant, Databricks, explores why our current education system still falls short in helping female students navigate careers in tech.
Targeted neuromodulation may be a future method to help those with severe, untreatable depression - traditionally, this is used to correct misfiring brain circuits in people with epilepsy or Parkinson's.
The destruction of the Amazon rainforest influences how much carbon is released - now, scientists reveal that damaged, not-yet-destroyed areas are releasing carbon faster than the rainforest can store it.
Dr Eduardo Bianco, Chair of the Tobacco Expert Group at the World Heart Federation discusses the ongoing battle to end the tobacco epidemic, and how e-cigarettes may be part of the problem.
Here, Richard Beardsworth, Professor of International Relations at the University of Leeds, continues his series on the nature of progressive state leadership, pondering a new normative framework for political action and climate leadership.
Frederique Lisacek from SIB Swiss Institute of Bioinformatics, discusses the experimental approaches towards Glycoscience and emphasises the need for collecting and integrating glyco-related information.
The "COVID pill" by Merck, found to halve virus hospitalisation and death rates, will be sold in the US at $712 per treatment - while costing $17.74 to produce.
Paul Ekins, Professor of Resources and Environmental Policy, University College London, tells us about UCL’s COP26 Campaign ‘Together for Climate Action’.
